SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Report abuse about a comment

Sponsors involved as well

One should not forget that CROs still work for sponsors and do not conduct trials for themselves. The fact that sales outside the US have grown that much demonstrates that the big pharma , which is by far the biggest client of global CROs, is more and more interested in selling its products outside the US market. This is particularly true for emerging countries such as Brasil or India. And since it is way easier to get registration and to sell its drug, in Brasil for example, once trials have been conducted in the country, sponsors ask for CROs to have an international expansion. Therefore it is not only the CROs that are globalising, it is the whole pharma industry.

Posted by Guillaume Miara
30 August 2011 | 15h30

Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.

Your name *
Your email *

We will not publish your email on the site

Reason *

Back to: Over 50% of sales at top CROs now made outside US; report

Spotlight

Medidata: Digital biomarkers are the future of clinical trials

Medidata: Prepare to embrace digital biomarkers in trials or lose competitiveness

The advent of Big Data in clinical trials will mean companies not using digital biomarkers are unlikely...

More details on Cetero/PRACS implosion come to light

More details on Cetero/PRACS implosion come to light

Lachman Consultants has revealed more of the story behind the decline of the now bankrupt CRO Cetero/PRACS,...

UK Hospitals to play part in Gov efforts to speed clinical trial process

UK Hospitals to play part in Gov efforts to speed clinical trial process

UK life sciences minister George Freeman wants hospitals to play more of a role in clinical trials...

Quintiles CEO: Innovation coming from CROs takes pressure off pharma
Dispatches from FT Global Pharmaceutical and Biotechnology conference, London

Quintiles CEO: Change in R&D paradigm must come from Pharma's boardrooms

Vertical integration is inhibiting pharma R&D innovation, according to Quintiles CEO Tom Pike who says executives must...

New Ricerca CEO remains positive as questions linger over company

New Ricerca CEO remains positive as questions linger over company

As questions continue to be raised over why Ricerca was on the brink of closure and laying...

'Killer experiments' and reimbursement are the keys to VC backing says Index

'Killer experiments' and reimbursement are the keys to VC backing says Index

Investors only back drug innovators because they have to according to Index Venture Management's Kevin Johnson, who...

Key Industry Events

 

Access all events listing

Our events, Events from partners...